Literature DB >> 16261175

Molecular defects in T- and B-cell primary immunodeficiency diseases.

Charlotte Cunningham-Rundles1, Prashant P Ponda.   

Abstract

More than 120 inherited primary immunodeficiency diseases have been discovered in the past five decades, and the precise genetic defect in many of these diseases has now been identified. Increasing understanding of these molecular defects has considerably influenced both basic and translational research, and this has extended to many branches of medicine. Recent advances in both diagnosis and therapeutic modalities have allowed these defects to be identified earlier and to be more precisely defined, and they have also resulted in more promising long-term outcomes. The prospect of gene therapy continues to be included in the armamentarium of treatment considerations, because these conditions could be among the first to benefit from gene-therapy trials in humans.

Entities:  

Mesh:

Year:  2005        PMID: 16261175     DOI: 10.1038/nri1713

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  54 in total

Review 1.  Regulation of mucosal IgA responses: lessons from primary immunodeficiencies.

Authors:  Andrea Cerutti; Montserrat Cols; Maurizio Gentile; Linda Cassis; Carolina M Barra; Bing He; Irene Puga; Kang Chen
Journal:  Ann N Y Acad Sci       Date:  2011-11       Impact factor: 5.691

2.  Impaired pneumovax-23-induced monocyte-derived cytokine production in patients with common variable immunodeficiency.

Authors:  Raymond Hong; Sudhanshu Agrawal; Sastry Gollapudi; Sudhir Gupta
Journal:  J Clin Immunol       Date:  2010-02-23       Impact factor: 8.317

3.  Impact of a physician education and patient awareness campaign on the diagnosis and management of primary immunodeficiencies.

Authors:  Diana Pickett; Vicki Modell; Ian Leighton; Fred Modell
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

Review 4.  The role of platelet CD154 in the modulation in adaptive immunity.

Authors:  Daniel L Sprague; Jennifer M Sowa; Bennett D Elzey; Timothy L Ratliff
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

Review 5.  Regulatory T cells and B cells: implication on autoimmune diseases.

Authors:  Ping Wang; Song Guo Zheng
Journal:  Int J Clin Exp Pathol       Date:  2013-11-15

6.  Postnatal tissue-specific disruption of transcription factor FoxN1 triggers acute thymic atrophy.

Authors:  Lili Cheng; Jianfei Guo; Liguang Sun; Jian Fu; Peter F Barnes; Daniel Metzger; Pierre Chambon; Robert G Oshima; Takashi Amagai; Dong-Ming Su
Journal:  J Biol Chem       Date:  2009-12-02       Impact factor: 5.157

7.  Global study of primary immunodeficiency diseases (PI)--diagnosis, treatment, and economic impact: an updated report from the Jeffrey Modell Foundation.

Authors:  Vicki Modell; Bonnie Gee; David B Lewis; Jordan S Orange; Chaim M Roifman; John M Routes; Ricardo U Sorensen; Luigi D Notarangelo; Fred Modell
Journal:  Immunol Res       Date:  2011-10       Impact factor: 2.829

8.  From genotype to phenotype. Further studies measuring the impact of a Physician Education and Public Awareness Campaign on early diagnosis and management of primary immunodeficiencies.

Authors:  Fred Modell; Diana Puente; Vicki Modell
Journal:  Immunol Res       Date:  2009       Impact factor: 2.829

9.  Immunoglobulin D enhances immune surveillance by activating antimicrobial, proinflammatory and B cell-stimulating programs in basophils.

Authors:  Kang Chen; Weifeng Xu; Melanie Wilson; Bing He; Norman W Miller; Eva Bengtén; Eva-Stina Edholm; Paul A Santini; Poonam Rath; April Chiu; Marco Cattalini; Jiri Litzman; James B Bussel; Bihui Huang; Antonella Meini; Kristian Riesbeck; Charlotte Cunningham-Rundles; Alessandro Plebani; Andrea Cerutti
Journal:  Nat Immunol       Date:  2009-06-28       Impact factor: 25.606

10.  Analysis of TACI mutations in CVID & RESPI patients who have inherited HLA B*44 or HLA*B8.

Authors:  Manda L Waldrep; Yingxin Zhuang; Harry W Schroeder
Journal:  BMC Med Genet       Date:  2009-09-23       Impact factor: 2.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.